BioLife Solutions Inc (BLFS)
Solvency ratios
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt-to-assets ratio | 0.01 | 0.02 | 0.03 | 0.04 | 0.04 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-capital ratio | 0.01 | 0.02 | 0.03 | 0.04 | 0.05 | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-equity ratio | 0.01 | 0.02 | 0.03 | 0.05 | 0.05 | 0.06 | 0.07 | 0.07 | 0.07 | 0.06 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial leverage ratio | 1.14 | 1.17 | 1.17 | 1.20 | 1.22 | 1.24 | 1.23 | 1.25 | 1.24 | 1.20 | 1.15 | 1.14 | 1.16 | 1.14 | 1.15 | 1.15 | 1.15 | 1.05 | 1.08 | 1.40 |
The solvency ratios of BioLife Solutions Inc indicate a stable financial position over the analyzed period. The Debt-to-assets ratio remained relatively low, steadily increasing from 0.00 in the first quarter of 2020 to 0.04 by the end of December 2024. This suggests that the company's total debt in relation to its total assets has been well managed.
Similarly, the Debt-to-capital ratio also exhibited a gradual increase, from 0.00 in early 2020 to 0.01 by December 2024. This ratio signifies the proportion of debt in relation to the total capital employed by the company, showing that BioLife Solutions has maintained a conservative approach to financing its operations.
The Debt-to-equity ratio, which reflects the level of debt compared to shareholder equity, showed a similar trend, rising from 0.00 to 0.01 in early 2020 to 0.01 to 0.03 by the end of December 2024. This indicates that the company has primarily relied on equity financing rather than debt to support its operations.
The Financial Leverage ratio also demonstrated a consistent pattern, fluctuating between 1.05 and 1.25 over the analyzed period. Despite some variability, the ratio remained within a reasonable range, indicating that BioLife Solutions has effectively managed its financial leverage to support growth and maintain financial stability.
In conclusion, based on the solvency ratios analyzed, BioLife Solutions Inc appears to have maintained a sound financial position with a prudent approach to managing debt and capital structure.
Coverage ratios
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest coverage | -15.68 | -33.10 | -96.59 | -325.34 | -5,447.92 | -237.12 | -195.00 | -321.66 | -234.74 | -405.42 | -244.44 | -72.79 | -81.39 | -66.58 | -85.64 | -1,195.00 | -122.00 | 1,560.25 | 8,820.50 | 12,758.00 |
The interest coverage ratio measures a company's ability to cover its interest expenses with its operating income. A higher ratio indicates that the company is more capable of meeting its interest obligations.
Looking at the data provided for BioLife Solutions Inc's interest coverage from March 31, 2020, to December 31, 2024, there is a notable fluctuation in the company's ability to cover its interest expenses.
The interest coverage ratio was exceptionally high at 12,758.00 on March 31, 2020, but it declined significantly in the following quarters. By December 31, 2020, the interest coverage ratio had turned negative, indicating that the company's operating income was insufficient to cover its interest expenses.
The negative trend continued through 2021 and 2022, with persistently low and deteriorating interest coverage ratios. The company's ability to cover its interest expenses improved slightly in the subsequent quarters of 2023 but remained negative.
Notably, by December 31, 2023, the interest coverage ratio reached a substantial negative value of -5,447.92, suggesting significant financial strain in meeting interest obligations. However, from March 31, 2024, there seems to be a gradual improvement in the interest coverage ratio, suggesting a potential turnaround in the company's ability to cover its interest expenses.
Overall, the data indicates a volatile and challenging financial situation for BioLife Solutions Inc in terms of covering its interest payments. Investors and creditors may closely monitor this ratio to assess the company's financial health and ability to manage its debt obligations effectively.